Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
AstraZeneca
Merck
Express Scripts
Colorcon

Last Updated: January 23, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Sitravatinib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Sitravatinib?

Sitravatinib is an investigational drug.

There have been 26 clinical trials for Sitravatinib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 15th 2019.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Non-Small-Cell Lung, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Mirati Therapeutics Inc., BeiGene, and M.D. Anderson Cancer Center.

There are thirty-one US patents protecting this investigational drug and two hundred and eighty-nine international patents.

Recent Clinical Trials for Sitravatinib
TitleSponsorPhase
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCMirati Therapeutics Inc.Phase 2
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCSarah GoldbergPhase 2
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic MelanomaBeijing Cancer HospitalPhase 2

See all Sitravatinib clinical trials

Clinical Trial Summary for Sitravatinib

Top disease conditions for Sitravatinib
Top clinical trial sponsors for Sitravatinib

See all Sitravatinib clinical trials

US Patents for Sitravatinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sitravatinib ⤷  Try it Free Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Try it Free
Sitravatinib ⤷  Try it Free Methods of treating pediatric cancers Loxo Oncology, Inc. (Stamford, CT) ⤷  Try it Free
Sitravatinib ⤷  Try it Free Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Try it Free
Sitravatinib ⤷  Try it Free Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Try it Free
Sitravatinib ⤷  Try it Free Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Loxo Oncology, Inc. (Stamford, CT) ⤷  Try it Free
Sitravatinib ⤷  Try it Free Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Try it Free
Sitravatinib ⤷  Try it Free Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sitravatinib

Drugname Country Document Number Estimated Expiration Related US Patent
Sitravatinib Australia AU2016291676 2035-07-16 ⤷  Try it Free
Sitravatinib Brazil BR112018000808 2035-07-16 ⤷  Try it Free
Sitravatinib Canada CA2992586 2035-07-16 ⤷  Try it Free
Sitravatinib Chile CL2018000119 2035-07-16 ⤷  Try it Free
Sitravatinib China CN108349969 2035-07-16 ⤷  Try it Free
Sitravatinib Denmark DK3322706 2035-07-16 ⤷  Try it Free
Sitravatinib Eurasian Patent Organization EA035049 2035-07-16 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
AstraZeneca
Merck
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.